SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…
Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates…
STRASBOURG, France, July 9, 2025 /PRNewswire/ -- The International Human Frontier Science Program Organization (HFSPO) is pleased to award the…